Argitalpenak (14) IOANA MARCELA CROITORU argitalpenak

2024

  1. A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Long Non-Coding RNA Profile in Genetic Symptomatic and Presymptomatic Frontotemporal Dementia: A GENFI Study

    Journal of Alzheimer's Disease, Vol. 100, Núm. s1, pp. S187-S196

2023

  1. Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease

    npj Parkinson's Disease, Vol. 9, Núm. 1

  2. Falls Predict Acute Hospitalization in Parkinson's Disease

    Journal of Parkinson's disease, Vol. 13, Núm. 1, pp. 105-124

  3. Frequency and phenotypic spectrum of spinocerebellar ataxia 27B and other genetic ataxias in a Spanish cohort of late-onset cerebellar ataxia

    European Journal of Neurology, Vol. 30, Núm. 12, pp. 3828-3833

2022

  1. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

2021

  1. A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene

    Frontiers in Neurology, Vol. 12

  2. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils

    Acta Neuropathologica, Vol. 142, Núm. 3, pp. 475-494

2020

  1. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

    The Lancet Neurology, Vol. 19, Núm. 1, pp. 71-80

  2. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients

    Annals of Clinical and Translational Neurology, Vol. 7, Núm. 10, pp. 1816-1830

2019

  1. Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test)

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 50-56

  2. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

  3. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

2016

  1. Fingolimod: Effectiveness and safety in routine clinical practice. an observational,retrospective,multi-centre study in Navarra,Gipuzkoa and La Rioja

    Revista de Neurologia, Vol. 63, pp. S5-S11